• Product name

    Anti-EBV gp340/220 Envelope Protein antibody [10B5]
  • Description

    Mouse monoclonal [10B5] to EBV gp340/220 Envelope Protein
  • Host species

  • Specificity

    This antibody is specific for Epstein-Barr Virus.
  • Tested applications

    Suitable for: ELISA, ICC/IFmore details
  • Species reactivity

    Reacts with: Other species



Our Abpromise guarantee covers the use of ab6525 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA 1/800.
ICC/IF Use at an assay dependent dilution.


  • Relevance

    Epstein-Barr virus is a member of the herpesvirus family and one of the most common human viruses. The envelope glycoprotein Gp340/Gp220 is the most abundant vomponent of the viral envelope and is believed to be responsible for EBV binding to CR2 receptor on human B-Cells.
  • Cellular localization

    Virion membrane: most abundant component of the viral envelope.
  • Alternative names

    • BLLF1a antibody
    • Envelope glycoprotein Gp220/340 antibody
    • Envelope glycoprotein GP340/220 antibody
    • Envelope glycoprotein GP340/GP220 antibody
    • Epstein Barr gp350 envelope protein antibody
    • Epstein Barr virus antibody
    • Epstein Barr Virus envelope glycoprotein complex 250/350 antibody
    • gp 350 antibody
    • Gp350 antibody
    • MA antibody
    • Membrane antigen antibody
    see all


ab6525 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

1-3 of 3 Abreviews or Q&A


Thank you for your enquiry. I am sorry for the delay in a response to your enquiry. I have performed a literature search and it seems that your approach is certainly suitable for the detection of EBV: http://www.clinchem.org/cgi/reprint/50/10/1814 In the above publication they superinduced the lytic cycle by the use of the histone deacetylase inhibitor Sodium Butyrate. I was wondering whether you had considered this approach to get a firm positive control from your P3HR1 cells: "gp350/220 mRNAs was quantified in the EBV-infected cell lines P3HR1, B95-8, and Akata. The P3HR1 and B95-8 B-cell lines spontaneously release viral particles. Moreover, the EBV lytic cycle can be superinduced by treatment with 30 ug/L 12-tetradecanoylphorbol 13-acetate and 3 mmol/L sodium butyrate" We do have some excellent ELISA protocols available as PDF files at the following location. I was wondering whether you were using a similar approach: http://ops.abcam.com/index.html?pageconfig=resource&rid=10417 If you continue to have difficulties with this antibody I would appreciate it if you could complete our on line technical questionnaire by clicking on the following link. This will better enable our technical team to determine the steps that you have taken to optimise this antibody. https://www.abcam.com/index.html?section=elisa&pageconfig=technical&intAbID=6525&mode=questionaire I look forward to hearing from you.

Read More


Thank you for your enquiry. The information on our datasheet was slightly incorrect. I have updated the information to include the ELISA dilution information :ELISA Titer: 0.100 @ >1:800. The nomenclature that is employed here refers to the dilution at which an absorbance of 0.1 is achieved. Therefore in this case an absorbance of 0.1 was generated using a dilution of 1:800 or more. I hope this information helps, please do not hesitate to contact me should you require further assistance.

Read More

For licensing inquiries, please contact partnerships@abcam.com

Sign up